Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
The funding round was led by Triple Point Ventures with backing from StartUp Health, Plug and Play Ventures, and YZR Capital.
"We’re incredibly excited to use this latest round of funding to empower even more people to take their healthcare into their own hands, by making diagnostic imaging accessible to everyone, everywhere."
The pre-seed round was led by QUBIS Innovation Fund and will support clinical trial preparations and engineering hires.
"We are delighted to have led this investment round into Transdermal Diagnostics. The transdermal approach for glucose monitoring that Transdermal Diagnostics is developing will have a disruptive impact on the diabetes market, we are additionally excited by the company’ potential to expand into the wellness and sports nutrition industries. This funding round alongside the Innovate UK funding will help support them in this journey."
The Series A round was led by AlbionVC with participation from HTH and InHealth Ventures.
"Over the last six years, we have been creating and developing our patient-centric sensor-based technology and platform to transform neuro-rehab. In clinical studies, NeuroBall was proven to motivate patients to do hundreds of movement repetitions independently at home, which led to significant improvements in the range of motion, reduction of arm pain and return to daily activities using their arm and hand after a stroke. This has proven transformative to neuro-rehab as previously patients would not have access to in-person physical or occupational therapy due to factors such as insurance, financial, transportation and health barriers. We’re excited to partner with AlbionVC, HTH, and InHealth Ventures, and are hugely grateful for their support to scale our unique neurological therapeutics platform that we believe will change the world of neuro-rehab."
The seed round was led by Faber with participation from international venture funds to support clinical trial operations.
"For hundreds of years, treatments have been developed with the assumption they will work for everyone. However, each person is different, and for many severe diseases such as Alzheimer’s, multiple factors can contribute to the effectiveness of a treatment on a given patient."
The oversubscribed venture round was structured under a convertible loan note with participation from existing investors.
"we’re pleased to welcome onboard our new partners at Serafund, who bring unique insights from building and backing world-class technology businesses. We’re also grateful for the support from our existing investors, who remain as convicted as ever to the vision of transforming the patient experience and pharmaceutical value chain through digitally enabling thousands of high street pharmacies."
